We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+14.65%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$331M
AUM Growth
+$11.7M
Cap. Flow
-$13.4M
Cap. Flow %
-4.06%
Top 10 Hldgs %
42.42%
Holding
75
New
12
Increased
16
Reduced
23
Closed
21

Top Buys

1
NVO
Novo Nordisk
NVO
+$14.7M
2
BPMC
Blueprint Medicines
BPMC
+$9.93M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$8.99M
4
JANX icon
Janux Therapeutics
JANX
+$6.09M
5
DYN icon
Dyne Therapeutics
DYN
+$3.98M

Top Sells

1
BHVN icon
Biohaven
BHVN
+$19.1M
2
VRDN icon
Viridian Therapeutics
VRDN
+$8.38M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$8.04M
4
SLNO
Soleno Therapeutics
SLNO
+$7.18M
5
PCVX icon
Vaxcyte
PCVX
+$6.31M

Sector Composition

1 Healthcare 83.31%

No holdings matched the selected filter criteria.

1 2 3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Ghost Tree Capital held 75 positions worth $331M, up 3.7% from $319M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ghost Tree Capital withdrew a net $13.4M in Q3 2024, closing 21 positions and reducing 23 holdings. Its most notable exit was Biohaven, an estimated $19.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 90% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Novo Nordisk worth $13.1M.

  • Ghost Tree Capital's largest Q3 2024 buy was Novo Nordisk: 110,000 shares worth $13.1M.
  • Ghost Tree Capital added most to Blueprint Medicines in Q3 2024, an estimated $9.93M increase.
  • Ghost Tree Capital's biggest Q3 2024 reduction was Viridian Therapeutics, cutting an estimated $8.38M.
  • Ghost Tree Capital fully exited Biohaven in Q3 2024, selling an estimated $19.1M.
  • Ghost Tree Capital's ten largest holdings make up 42% of its $331M portfolio in Q3 2024.
  • Ghost Tree Capital opened 12 new positions and closed 21 in Q3 2024.
  • Ghost Tree Capital's portfolio value rose 3.7% quarter-over-quarter to $331M.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.